Impact of donor-specific antibodies on long-term graft survival with pediatric liver transplantation

Table 2 Biopsy characteristics

	Group 1: ‘DSA-positive’ (n = 38)	Group 2: ‘DSA-negative’ (n = 34)	P value
Fibrosis1	n = 24	n = 6
Low-grade	n = 23	n = 6	< 0.001
High-grade	n = 1	n = 0	0.5
Cirrhosis	n = 3	n = 0	0.5
Steatosis	n = 6	n = 6	0.8
Portal inflammation	n = 28	n = 18	0.005
Perivenular/perisinusoidal inflammation	n = 11	n = 2	0.011
Ductular inflammation	n = 13	n = 3	0.004
Endothelitis	n = 6	n = 2	0.1
Biliary lesions/ductulopenia	n = 6	n = 0	0.009
Ductular cholestasis	n = 12	n = 4	0.01
Biliary tract strictures	n = 9	n = 6	0.03
Single cell necrosis	n = 5	n = 0	0.02
Chronic rejection2	n = 7	n = 0	0.009
Possible camr3	n = 9	n = 0	0.002

¹Fibrosis grading according to Desmet et al.

²Chronic rejection according to Banff criteria.

³Chronic antibody-mediated rejection (camr) according to Banff 2016 criteria, with absent C4d staining.

DSA: Donor-specific antibodies.